Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

Treatment with acetyl-CoA carboxylase inhibitors (ACCi) in nonalcoholic steatohepatitis (NASH) may increase plasma triglycerides (TGs), with variable changes in apoB concentrations. ACC is rate limiting in de novo lipogenesis and regulates fatty acid oxidation, making it an attractive therapeutic ta...

Full description

Bibliographic Details
Main Authors: Mohamad Dandan, Julia Han, Sabrina Mann, Rachael Kim, Kelvin Li, Hussein Mohammed, Jen-Chieh Chuang, Kaiyi Zhu, Andrew N. Billin, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Marc Hellerstein
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Journal of Lipid Research
Subjects:
nonalcoholic steatohepatitis
LDL
lipoproteins
lipoproteins/kinetics
lipoproteins/metabolism
triglycerides
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227523000123

Internet

http://www.sciencedirect.com/science/article/pii/S0022227523000123

Similar Items